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Chapter 1. General introduction 
Utilization of shark for foods, cosmetics and medicines-history and 
recent trend. 
Shark belongs to the subclass Elasmobranchii of the class Chondrichthyes, with 
the branchial clefts opening on the sides of the body. About 500 species are widely 
distributed in the oceans of the earth, and some are known to inhabit brackish water and 
fresh water.  
The first record of shark meat as food was observed in Engi Shiki in Japan. It was 
prepared and paid to government as tax in Heian era (Narita et al.; 2001). Since sharks 
use urea for the regulation of the osmotic pressure of body fluids, urea accumulates in 
their muscle. As shark meat emits the smell of ammonia, when freshness is lost. 
Frequently, shark meat are ground into paste and used as Surimi for Kamaboko and 
Hanpen. On the other hand, transparent fibers on the both side of shark fins cartilage are 
used for high grade Chinese cuisine. In some cases, shark is discarded to sea except for 
fins. Shark has cartilage as endskeletal and large liver and has unique compounds in body. 
Shark has，therefore, attracted attention as source for pharmaceutical and functional food 
ingredients. Shark liver oil is rich in squalene. squalane, diacyl glyceride and so on. 
Squalene and squalen have been demonstrated to exert beneficial effects such as 
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maintaining skin functions and improving the liver and immune functions. Diacyl 
glyceryl ethers have also been reported to enhance immune system, inhibit cancer 
progress, maintain skin functions (Nobuto et al.;1988, Nobuto et al.; 1987, Brohult et al.; 
1970, Homma et al.;1990, Nishikawa et al.; 2011), and attenuate the damages by 
radiation (Brohult et al.; 1958, Brohult et al.; 1954, Alexander et al.; 1959).  
In addition to liver oil, shark cartilage has been used to produce beneficial 
ingredients for foods, cosmetics and medicines. The skeleton of the shark, a cartilaginous 
fish, is made up entirely of cartilage, which primarily consists of calcium, their salt, 
collagen and proteoglycans. Proteoglycan is a complex of non-collagenous core protein 
and mucopolysaccharides. Chondroitin sulfate, hyaluronic acid, and keratan sulfate are 
main mucopolysaccharide in proteoglycans in shark cartilage. Shark cartilage has been 
used as a folk medicine to moderate rheumatoid arthritis, osteroarthritis. It has been also 
used for enhancement of the wound healing and the treatment of non-tumorous chronic 
inflammatory diseases since the 1950s to 1990s. Recently, highly purified chondroitin 
sulfate or chondroitin sulfate sodium is used for the treatment of low back pain, arthralgia, 
shoulder periarthritis by injection (Hiroaki et al.; 1994, Jackson et al.; 1953, Hochberg et 
al.; 2008), and for the protection of the superficial layer of the cornea as eye drops 
(Embriano; 1989). Animal experiments have also demonstrated potential beneficial 
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activities of shark cartilage compounds. Moses et al. discovered that shark cartilage has 
an anti-angiogenic action in the 1990s (Moses et al.; 1990), and reported the possibility 
that this action is derived from the inhibition of matrix metalloproteinases 
(MMPs)(Moses et al.; 1991, Moses et al.; 1992, Folknan; 1995), which are involved in 
tumors proliferation and metastasis (Hidalgo et al.; 2001, Gonzalez et al.;2001).  To 
confirm the antitumor effect of crude shark cartilage powder and their extract, clinical 
studies have been initiated (Marwick et al.; 2001, Ernst; 1998, Miller et al.; 1998, 
Tsukasa et al.; 2012, Tsukasa et al.; 2006). However, controversial results have been 
reported. Some studies showed disappointed results possibly due to the difficulty in 
administration of effective dose of shark cartilage for cancer patient (Murata et al.; 2002). 
Then, efforts have been made to extract active components from shark cartilage to reduce 
dosage necessary for the beneficial activities. After crushing of dried shark cartilage to 20 
m by freeze fracturing mill. Significant amounts of proteoglycan and other compounds 
can be extracted with water (Murota et al.; 2014). It has been demonstrated that the water 
extract of shark cartilage increases serum inhibitory activities against MMP-2 and 
MMP-9 and suppress progression of pancreatic duct cancer in animal model.  These 
effects were not observed in a water extract of bovine cartilage prepared by the same 
method (Tsukasa et al.; 2012, Tsukasa et al.; 2006). These reports suggest that the 
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anticancer component contained in shark cartilage can be extracted under moderate 
conditions using water, which can reduce dose compared to shark cartilage powder. 
Recently in Japan, a field of medicine referred to as complementary and alternative 
medicine (Suzuki; 2004), characterized by combining treatments of Western medicine and 
traditional treatments including those of oriental medicine, has rapidly emerged. 
Concerning cancer treatment, the Japanese Society for Palliative Medicine prepared the 
“Guidelines for Complementary and Alternative Treatments for Cancer” as a project 
sponsored by the Cancer Research Subsidy of the Ministry of Health, Labor and Welfare. 
Shark cartilage is positive mentioned in the guidelines (Sumiyoshi; 2006, Suzuki; 2006), 
and the results reported by Murata may accelerate this approach.  
 
Background of the present study-Gout and Anti-hyperuricemic activity of protease 
digest of shark cartilage. 
The present study originated from the research aimed to identify novel 
pharmacological effects of edible chondroitin sulfate, which is a food-grade crude 
protease digest of shark cartilage. Blood biochemical parameters were checked after two 
weeks administration of the food-grade crude protease digest of shark cartilage in rat 
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(1g/kg body weight). Fall tendency of serum uric acid was observed, which initiated the 
present study. 
Uric acid tends to crystallize in blood more than 7 mg/dl (Nuget et al.;1959). The 
crystal deposits in joints, tendons, and surrounding tissues, which induce sever 
inflammation, namely gout. Gout is a medical condition usually characterized by 
recurrent attacks of acute inflammatory arthritis – red, tender, hot, swollen joint. The 
metatarsal – phalangeal joint at the base of the big toe is most commonly affected. 
Formation of uric acid crystal and the conversely dissolution depend on the concentration 
of uric acid, pH, sodium concentration, and temperature. Hyperuricemia is, therefore, one 
of important risk factors for the onset of gout (Hall et al.; 1967, Campion et al.; 1987, 
Terkeltaub; 2010, Weaver; 2008).  To treat gout, chemically synthesized drugs – 
allopurinol, benzbromarone, probenecid and so on, which are based on inhibition of uric 
acid synthesis or enhancement of urinary excretion of uric acid, have been clinically 
used; however, occasional side effects of these medicines are a stumbling block for 
chronic use. In spite of their low frequency, the side effects of allopurinol could be 
life-threatening and occur more often in patients with renal insufficiency (Fam; 1998, 
Harris et al.; 1999, Lipshultz et al.; 2003, Schlesinger et al.; 2004). 
8 
 
Many factors, including genetics, insulin resistance, hypertention, renal 
insufficiency, obesity, diet, and use of diuretics, contribute to hyperuricemia. Gout is, 
therefore, a life-style related disease. Dietary factors have been estimated to account for 
about 12% of causes of gout (Chen et al.; 2008). With the change in eating habits, gout 
has become prevalent worldwide.  Onset of gout has a strong association with the 
consumption of alcohol, fructose-sweetened drinks, meat, and seafood (Terkeltaub; 2010, 
Weaver; 2008). A ketogenic diet impairs the ability of the kidney to excrete uric acid, due 
to competition for transport between uric acid and ketones (Forster; 1979). The gene 
SLC2A9 encodes a protein that helps to transport uric acid into renal cytomembrane. 
Several single nucleotide polymorphisms of this gene are known to have a significant 
correlation with blood uric acid (Brandstatter et al.; 2008). In addition, it has been 
demonstrated that hyperuricemia is closely associated with other lifestyle-related diseases 
(Hosoya; 2008) .  
Uric acid is the final metabolite of endogenous and food-derived purine bases in 
humans. To control the blood uric acid level, patients suffering from hyperuricemia are 
encouraged to consume foods with a low-purine content. For this purpose, low-purine 
alcoholic beverages are commercially available in Japan (Shibano et al.;1996, Tofler et 
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al.; 1981). However, it is difficult for individuals to control their blood uric acid level 
only using low-purine foods.  
      The preliminary experiment using normal rat suggested that oral administration of 
protease digest of shark cartilage has potential to moderate hyperuricemia. The present 
study was carried out to confirm the anti-hyperuricemic effect of the protease digest of 
shark cartilage using oxonate-induced hyperuricemic rat model. In addition, the present 
study aimed to identify the active component. 
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Chapter 2. 
Uric acid lowering effect by ingestion of proteolytic digest of shark 
cartilage and its basic fraction 
 
ABSTRACT 
Supplementing with proteolytic digest of shark cartilage to give 1.5% and 2.5% 
in the diet significantly moderated hyperuricemia in rats induced by potassium oxonate in 
the diet. On the other hand, no significant effect was observed by a diet containing 2.5% 
proteolytic digest of cow cartilage. Hyperuricemia induced by a single intraperitoneal 
injection of potassium oxonate was also moderated by single ingestion of the proteolytic 
digest of shark cartilage in a dose-dependent manner. The proteolytic digest of shark 
cartilage was fractionated on the basis of the isoelectric point into acidic, weak acidic and 
basic fractions. Significant anti-hyperuricemic activity was observed only in the basic 
fraction, and ingestion of chondroitin sulfate free from protein, one of the major 
constituents of the digest, had no significant anti-hyperuricemic activity. Basic 
components, possibly peptide, might be responsible for anti-hyperuricemic activity in this 
rat model. 
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INTRODUCTION  
 As described chapter 1., patients suffering from gout are encouraged to eat foods 
with low purine content to control the blood uric acid level by food, as uric acid is also a 
metabolite of food-derived purine. For the patient suffering from gout, low purine 
beverages have been developed (Fukui; 2011, Fukuuchi et al.; 2013). Recently, it has 
been reported that oral ingestion of chitosan can moderate hyperuricemia by suppressing 
absorption of purine into blood (Shirogane et al.; 2004). To the best of our knowledge, 
there are few peer-reviewed papers have demonstrated that ingestion of food components 
display anti-hyperuricemic activity based on xanthine oxidase inhibition.  
Shark cartilage consists of proteoglycan, collagen and various proteins with 
biological activities (Lee et al.; 1984). Highly purified chondroitin sulfate C, 
polysaccharide moiety of proteoglycan, has been used for medical purposes (Ameya et 
al.; 2006) . In addition to medical products, various forms of shark cartilage products 
have been prepared as food ingredients. It has been suggested that these products might 
have beneficial effects on patients suffering from cancer, osteoarthritis, rheumatoid 
arthritis and so on, although their efficacy is controversial (Miller et al.; 1998, Hyodo et 
al.; 2005). Recently, a food-grade proteolytic digest of shark cartilage has been prepared 
on an industrial scale (Murota et al.; 2003). As mentioned chapter 1., in the preliminary 
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experiment, it was observed that ingestion of the proteolytic digest of shark cartilage 
tended to decrease the serum uric acid level of normal rat, suggesting that the digest has 
the potential to moderate hyperuricemia.  
Rats have uricase which metabolizes uric acid to allantoin. Then, rats has low 
serum uric acid. Therefore, normal rats are not suitable for anti-hyperuricemic research. 
For this purpose, potassium oxonate-induced hyperuricemic rat model has been 
established. Potassium oxonate is an uricase inhibitor. It was checked in advance that the 
digest did not affect uricase activity. 
The objectives of chapter 2. were to confirm the anti-hyperuricemic activity of 
the proteolytic digest of shark cartilage prepared in an industrial scale, using the 
potassium oxonate-induced hyperuricemic rat model and to estimate the component 
responsible for anti-hyperuricemic activity. 
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MATERIALS AND METHODS 
Materials and Reagents 
A crude proteolytic digest of shark cartilage was prepared on an industrial scale 
according to the method described by Murota et al (2006). Briefly, shark cartilage was 
suspended in water and heated in an autoclave at 12°C, before being digested with a 
food-grade Bacillus licheniformisprotease. The digest was clarified by filtration, passed 
through activated carbon, and then spray-dried. This product, referred to SCP, can be 
obtained commercially from Maruha Nichiro. (Tokyo, Japan). Analytical grade 
chondroitin sulfate and the Uric Acid Test Wako Kit were purchased from Wako Pure 
Chemicals (Osaka, Japan). Agarose powder was purchased from Nacalai Tesque (Kyoto, 
Japan). Potassium oxonate was purchased from Across Organics (Geel, Belgium). 
 
Fractionation of Components in digests of shark cartilage.  
The fractionation of components in the digest was performed by ampholyte-free 
preparative isoelectric focusing (autofocusing) according to the method of Hashimoto et 
al. (2005) using autofocusing apparatus with 10 sample compartments (75 mm in length x 
80 mm in width x 85 mm in height). The digest was dissolved in deionized water to give 
10% (w/v) and loaded into sample compartments No. 5 and 6. The other sample 
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compartments were filled with deionized water. Autofocusing was carried out 500 V for 
12 h.  
 
Animal Experiments 
Female Sprague-Dawley strain rats and male Wistar rats were purchased from 
Charles River Laboratories Japan (Yokohama, Japan). Male Sprague-Dawley strain rats 
were purchased from Japan SLC (Hamamatsu, Japan). All animals were caged in the 
same building and allowed free access to diet pellets and tap water. They were allowed to 
adapt to the environment for a week before being used. This study was conducted in 
accordance with the standards established by the guide for the care and use of laboratory 
animals of Maruha Nichiro Holdings Central Research Institute (Tsukuba City, Japan). 
Experiment 1. Hyperuricemia was induced by the method of Dan et al (1994). 
Nine-week-old female Sprague-Dawley strain rats (average body weight, 221.1 g) were 
fed a diet containing 2.5% (w/w) potassium oxonate (hyperuricemic; HU diet). Shark 
cartilage digest was supplemented to the HU diet to give 2.0% (SCP diet). The 
compositions of the HU and SCP diets are shown Table 1. Eighteen rats were fed the HU 
or SCP diet for 41 days. In addition, another 12 rats were fed the HU diet for 29 days and 
then divided into two groups; one group (n=6) continued to ingest the HU diet and 
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another group (n=6) was switched to the SCP diet for an additional 12 days. Rats were 
fasted for more than 12 h before blood drawing. The diets used in all experiments were 
prepared by Oriental Yeast (Tokyo, Japan). 
Experiment 2. Shark cartilage digest was suspended in distilled water at a test 
material concentration of 0.02–0.2 g/mL (w/v) and administered at a constant volume of 
5 mL/kg body weight to 8-week-old male Sprague-Dawley rats (average body weight, 
285.4 g) via a stomach sonde to give a dosage of 0.1, 0.3 and 1.0 g/kg body weight. One 
hour later, the rats were i.p. injected with potassium oxonate solution (250 mg/2 mL of 
3% gum arabic saline/kg body weight) to elevate the blood uric acid level (Osada et al.; 
1993). Whole blood samples were collected 1 h after oxonate injection. 
Experiment 3. Four-week-old male Sprague-Dawley rats (average body weight, 
140.1 g) were fed diets containing 3% potassium oxonate supplemented with Shark 
cartilage digest, cow cartilage digest or purified chondroitin sulfate (CS) for 28 days. Rats 
were fasted for more than 12 h before blood drawing.  
Experiment 4. Acidic, weak acidic and basic fractions of shark cartilage digest 
prepared by autofocusing were evaluated for their anti-hyperuricemic activity. The 
fractions were freeze-dried and re-suspended in distilled water and administered daily at a 
constant volume of 5 mL/kg body weight to 7-week-old female Sprague-Dawley rats 
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(average body weight, 201.3 g) to give a dosage 380, 250, 370 mg/kg body weight for 
acidic, weak acidic and basic fractions, respectively, via a stomach sonde. The dosage of 
each fraction was determined on the basis of the recovery of each fraction by 
autofocusing. The rats were fed a purified diet (Oriental Yeast) and administered with the 
test components for 22 days. Rats were fasted for more than 12 h before blood drawing. 
 
Preparation of Sera 
Blood was collected from the caudal artery, or the abdominal aorta under 
anesthesia and left to stand for 0.5–1 h at room temperature to clot. Serum was collected 
by centrifugation and stored at -30°C until used. 
 
Analytical Procedures 
Protein, mucopolysaccharide, lipid, moisture and heavy metals were determined 
according to the Association of Official Analytical Chemists method (1990). Amino acid 
analysis was performed according to the method of Bidlingmeyer et al. (1984) with a 
slight modification (Sato K et al.; 1992). Chondroitin sulfate was determined by the 
method of Bowness (1957). Serum uric acid was measured using an Uric Acid Test Wako 
Kit based on the phosphotungstic acid method. 
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Statistical Analyses 
Data are presented as the means±standard deviation. Differences between the 
means were evaluated by Student’s t-test with Holm adjustment (P=0.05) or analysis of 
variance followed by Dunnett, Bonferroni/Dunn or Fisher’s protected least significant 
difference method (P=0.05). Statistical studies were performed with StatView Version 5.0 
(SAS Institute, Cary, NC). 
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RESULTS 
Chemical Characterization of Crude and Fractionated Proteolytic Digest of Shark 
Cartilage 
The crude proteolytic digest of shark cartilage digest was characterized for its 
proximate composition and amino acid profile, as shown in Tables 2 and 3. The digest 
consisted of mainly peptide/protein and acidic polysaccharides containing uronic acid, 
namely mucopolysaccharide. Cellulose acetate electrophoresis and compositional 
analyses revealed that chondroitin sulfate C is a major constituent of the 
mucopolysaccharide fraction of the digest (data not shown). The digest contained 
hydroxyproline, a modified amino acid specifically distributed in collagen, at 3%. In 
collagen, hydroxyproline accounts for approximately 8% of the total amino acids. On the 
basis of these data, (the proteins in the digest) consisted of peptides derived from collagen 
(30%) and other proteins. 
The shark cartilage digest was fractionated by autofocusing. As shown in Fig. 1, 
pH gradient from 3 to 11 was formed. Fractions 1–6 showed approximately pH 3. On the 
basis of pH value after autofocusing, fractions 1–6, 7 and 8, and 9 and 10 were combined 
and used as the acidic, weak acidic and basic fractions in the following experiments, 
respectively. The acidic fraction was rich in chondroitin sulfate C. The weak acidic 
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fraction was rich in peptide. As shown in Fig. 2, collagen-specific amino acids 
(hydroxyproline and hydroxylysine) were distributed in all fractions in approximately the 
same ratio. The peptide in the acidic and weak acidic fractions showed comparable amino 
acid composition, while the basic fraction was characterized with smaller acidic amino 
acids and higher basic amino acids than other fractions. 
Experiment 1. The addition of potassium oxonate to the diet significantly 
increased the serum uric acid level to approximately 3.5mg/dl in the control group, as 
shown in Fig. 3A. On the other hand, supplementation of shark cartilage digest to the 
control diet suppressed potassium oxonate-induced hyperuricemia. Twenty-eight days 
after the administration of oxonate, the shark cartilage digest (SCP) group showed a 
significantly lower serum uric acid level than its counterpart. Rats fed the HU diet 
containing oxonate for 28 days showed significantly lower serum uric acid. The serum 
uric acid level continued to increase in the HU diet group, while it stopped increasing in 
the group switched to the SCP diet. Twelve days after the supplementation of SCP, the 
serum uric acid level was significantly lower in the SCP group (Fig. 3B). There was no 
difference in body weight gain among groups (data not shown). 
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Experiment 2. Hyperuricemia was also induced by a single i.p. injection of 
potassium oxonate. As shown in Fig. 4, oral administration of Shark cartilage digest 
decreased serum uric acid in a dose-dependent manner. 
Experiment 3. To compare the uric acid-lowering effect with shark cartilage 
digest, enzymatic hydrolysate of cow cartilage digest and purified shark CS were used. 
After supplementation with 2.5% cow cartilage digest and CS for 28 days, no significant 
uric acid-lowering effect was observed, while a significant effect was again observed in 
the SCP group (Fig. 5). There was no difference in body weight gain among groups (data 
not shown). 
Experiment 4.The components in shark cartilage digest were fractionated on the 
basis of the isoelectric point. After administration of test components for 22 days, only 
the basic fraction showed a significant uric acid-lowering effect even in smaller dosage 
than that of shark cartilage digest (Fig. 6). There was no difference in body weight gain 
among groups (data not shown).  
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DISCUSSION 
In the hyperuricemic rat model based on long-term ingestion of oxonate in the 
diet, supplementation of shark cartilage digest from the start and 29 days after oxonate 
administration suppressed the development of hyperuricemia. A similar effect was 
observed in both male and female rats of two strains. On the other hand, the proteolytic 
digest of cow cartilage digest does not have this potential activity. This suggests that 
shark cartilage digest has the potential to moderate hyperuricemia, which must be proven 
by clinical study. 
As shown in Table 2, SCP predominantly consists of mucopolysaccharides 
(chondroichin sulfate C) and peptides. The ingestion of purified shark chondroitin sulfate 
C did not show anti-hyperuricemic activity. This result is consistent with the acidic 
fraction, which contains a higher amount of chondroitin sulfate C, having no 
anti-hyperuricemic activity. On the other hand, the basic fraction showed higher 
anti-hyperuricemic activity. In addition, the water extract of shark cartilage without 
proteolytic digestion did not show a significant uric acid lowering effect (data not shown). 
These facts suggest that basic peptide fraction might be responsible for 
anti-hyperuricemic activity. 
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Amino acid analysis revealed that the protein/peptide fraction consists of 
collagen- and other protein-derived peptide; however, the active peptide has not been 
identified. The preliminary experiment revealed that the shark cartilage digest has no in 
vitro inhibitory activity against xanthinoxidase, which is a key enzyme for uric acid 
synthesis. Therefore, the in vitro assay system based on the inhibition of xanthinoxidase 
cannot be used for identification of the active peptide. In addition, the peptides in the 
microbial protease digest might be further degraded by peptidases in digestive tracts and 
blood of rat and change their biological activity. It is, therefore, the in vitro activity of 
peptide in the diet could not be directly linked to the in vivo activity of peptide. 
Interestingly, a single administration of shark cartilage digest can suppress transient 
elevation of serum uric acid by i.p. injection of oxonate in a dose-dependent manner, as 
shown in Fig. 4. Based on this result, in vivo activity-guided fractionation of the peptide 
is performed as mentioned in chapter 4., in order to identify the active component, which 
would allow us to elucidate the mechanism for uric acid-lowering effect. 
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TABLES AND GRAPHS 
Table 1. Composition of hyperuricemic and shark cartilage digest diets in 
experiment 1  
(%) 
 Hyperuricemic diet (HU diet) Shark cartilage digest diet (SCP diet)
Corn starch 38.0 38.0 
Casein 25.0 25.0 
α-corn starch 10.0 10.0 
Cellulose 8.0 8.0 
Soybean oil 6.0 6.0 
Mineral mix (Oriental) 6.0 6.0 
Vitamin mix (Oriental) 2.0 2.0 
sucrose 2.5 1.0 
Potassium oxonate 2.5 2.5 
Shark cartilage digest - 1.5 
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Table 2. Proximate composition of crude proteolytic digest of shark cartilage. 
Component  
Protein 53 % 
Mucopolysaccharide 43 % 
Lipid 0.01 % 
Moisture 4.1 % 
Heavy Metal less than 10 ppm 
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Table 3. Amino acid profiles of crude proteolytic digest of shark cartilage. 
Amino Acids (g/100g) Shark cartilage digest 
Hyp 3.6 
Asp 4.1 
Thr 2.2 
Ser 2.2 
Glu 5.8 
Pro 5.1 
Gly 10.7 
Ala 6.2 
Cys 2.0 
Val 1.7 
Met 3.9 
Ile 4.2 
Tyr 0.4 
Phe 1.3 
Lys 2.3 
His 0.7 
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Figure 1. PH gradient and contents of chondroitin sulfate C and peptide in the 
autofocusing fractions. 
Peptide content is expressed as sum of constituent amino acids. Acidic (A; Fr. 1–6), weak 
acidic (WA; Fr. 7 and 8), and basic (B; Fr. 9 and 10) were collected for the following 
experiments. 
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Figure 2. Amino acid composition of autofocusing fractions. 
Acidic; Asp and Glu after hydrolysis, neutral; sum of Ser, Gly, Thr, Ala, Pro, Tyr, Val, 
Met, Ile, Leu and Phe, basic; sum of His, Arg and Lys. Hyp and Hyl represent 
hydroxyproline and hydroxylysine, respectively. 
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Figure 3. Effects of supplementation of shark cartilage digest in hyperuricemic diet 
on development of hyperuricemia. 
(A) Rats received hyperuricemic (HU) or Shark cartilage digest (SCP) diet from the start 
of the experiment; (B) Rats received HU diet for 28 days and then received HU or SCP 
diet. The composition of HU and SCP diets is shown in Table 1. Data represent the means 
± standard deviation for 6 animals. * indicates significant difference between HU and 
SCP groups p< 0.05; Dunnett). Different letters (capital; SCP or switch-SCP, small; HU) 
indicate significant difference within a group (P < 0.05; Student’s t test with Holm 
adjustment). 
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Figure 4. Dose – dependent uric acid lowering effect of shark cartilage digest 
Rats received vehicle and shark cartilage digest in different dosages via stomach sonde 
and i.p. injected with potassium oxonate. Uric acid values were standardized against that 
of the vehicle group as 100. Data represent the means ± standard deviation for 6 animals. 
* indicates significant difference between vehicle and shark cartilage digest medication 
groups (P < 0.05; Dunnett). 
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Figure 5. Comparison of serum uric acid lowering effect with cow cartilage digest 
and purified chondroitin sulfate C. 
Rats were fed the HU diet containing 3% oxonate and supplemented diets with 2.5% 
shark cartilage digest (SCP), cow cartilage digest (CCP), or purified chondroitin sulfate C 
(CS). Uric acid values were standardized against that of the HU diet group as 100. Data 
represent the means ± standard deviation for 6 animals. Statistical significance between 
HU and CS was evaluated by Student’s t test. *indicates significant difference between 
HU and shark cartilage digest groups (P < 0.05; Dunnett). 
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Figure 6. Comparison of uric acid lowering effect of autofocusing fraction of shark 
cartilage digest. 
Uric acid values were standardized against that of the HU diet group as 100. Data 
represent the means ± standard deviation for 6 animals. Different letters indicate 
significant difference within groups (P < 0.05; Bonferroni/Dunn). 
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Chapter 3. 
Moderation of potassium oxonate-induced hyperuricemia in rats via the 
ingestion of an ethanol-soluble fraction of a shark cartilage proteolytic 
digest 
 
ABSTRACT 
A shark cartilage proteolytic digest was fractionated by selective extraction with 
75% ethanol. Peptides in the digest were recovered in the 75% ethanol-soluble fraction. 
The ethanol-soluble fraction showed lower viscosity and higher solubility in water than 
the crude digest. Oxonate-induced hyperuricemia in rat was suppressed by the oral 
administration of the ethanol-soluble fraction of the digest (1 g/kg body weight/day) for 
28 days. Single administration of the ethanol-soluble fraction also reduced blood uric acid 
level in a dose-dependent manner. A significant decrease in the serum uric acid level was 
observed at a dosage of 300 mg/kg. The 50% inhibitory dose value (ID50) of the 
ethanol-soluble fraction was estimated to be 262 mg/kg. Administration of the 
ethanol-soluble fraction of the digest (1 g/kg body weight/day) significantly increased 
serum inhibitory activity against xanthine oxidase, whereas the ethanol-soluble fraction 
had no in vitro xanthine oxidase inhibitory activity. These facts suggest that peptides in 
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the ethanol-soluble fraction might be converted into smaller peptides with xanthine 
oxidase inhibitory activity during digestion and absorption process. 
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INTRODUCTION 
In chapter 2., it is reported that ingestion of a shark cartilage proteolytic digest 
moderated hyperuricemia in a potassium oxonate induced rat model and suggested that 
peptide fraction might be responsible for the anti-hyperuricemic activity (Murota et 
al.;2010). However, the underlying mechanism for the anti-hyperuricemic activity of the 
digest has remained to be solved. In addition, the crude digest of shark cartilage showed 
high viscosity in water due to presence of chondroitin sulfate, which makes difficult to 
sallow it down by human subject. The objective of the present study was to prepare a 
peptide fraction with lower viscosity and higher anti-hyperuricemic activity from the 
crude digest, which is suitable for human trial.  
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MATERIALS AND METHODS 
Materials and reagents 
A proteolytic digest of shark cartilage was prepared in the same method as 
described in chapter 2. The digest was powdered and suspended in 75% ethanol and 
stirred for 60 min. After centrifugation at 3000g for 10 min, the supernatant was collected. 
Then, the extract was dried under vacuum and then resolved in a minimum amount of 
water, before being powdered by spray drying or freeze drying. A Wako Uric Acid Test 
Kit, bovine milk xanthine oxidase, xanthine and allopurinol was purchased from Wako 
Pure Chemical (Osaka, Japan). Potassium oxonate was purchased from Acros Organics 
(Geel, Belgium). 
 
Animals experiment 
 Female Sprague–Dawley rats and male Wistar rats were purchased from Charles 
River Laboratories Japan (Yokohama, Japan). All diet pellets were purchased from 
Oriental Yeast (Tokyo, Japan). All animals were housed (temperature: 22–24°C, 
humidity: 40–60%) under a 12 h light–dark cycle in the same building and given free 
access to their diet pellets and filtered water. The rats were allowed to adapt to their 
environment for a week before being used. This study was conducted in accordance with 
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the standards established by the Guide for the Care and Use of Laboratory Animals of 
Maruha Nichiro Holdings Central Research Institute (Tsukuba City, Japan). 
Experiment 1: Hyperuricemia was induced according to the method of Dan et al 
(1994).  Seven week-old female Sprague–Dawley rats (mean body weight of 199.8 g) 
were divided into three groups (n=7 for each group). Two of the groups were fed on a diet 
containing 2.5% (w/w) potassium oxonate (HU diet) for 28 days. The other group was fed 
on a normal diet. The compositions of the HU and normal diets are shown in Table 1. The 
ethanol-soluble fraction was suspended in distilled water at a concentration of 0.2 g/ml 
(w/v) and orally administered to the one of the HU groups once daily at a constant 
volume of 5 ml/kg body weight via a stomach sonde for 28 days. The other groups were 
administered with same volume of distilled water. The rats were fasted for 12 h before the 
blood collection from the abdominal aorta under anesthesia. 
Experiment 2: Seven-week-old female Sprague–Dawley rats (average body 
weight of 201.6 g) were divided into two groups (n= 6 for each group) and fed on a 
normal diet for 28 days. The ethanol-soluble fraction was suspended in distilled water at a 
concentration of 0.2 g/ml (w/v) and administered orally to one of the groups once daily in 
the same manner as in experiment 1. Another group was administered the same volume of 
distilled water. The rats were fasted for 12 h before their blood was collected. 
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Experiment 3: Hyperuricemia was induced according to the method of Osada et 
al. (1993) with slight modifications. Six-week-old male Wistar rats (mean body weight of 
161.2 g) were fed on a normal diet. The rats were divided into five groups (n= 6 for each 
group). Each test component was administered orally 2 h before the blood collection. The 
crude digest and the ethanol-soluble fraction were suspended in distilled water at a 
concentration of 0.2 g/ml (w/v) and administered orally at a constant volume of 5 ml/kg 
body weight to one group of rats each via a stomach sonde. Allopurinol was dissolved in 
water to give a concentration of 0.01 g/ml (w/v) and administered orally in the same 
manner as the crude digest and the ethanol-soluble fraction to another group of rats. One 
hour later, the rats were intraperitoneally injected with potassium oxonate solution (250 
mg/2 ml of 3% gum Arabic saline/kg body weight) in order to elevate their blood uric 
acid level. Whole blood samples were collected 1 h after the oxonate injection. 
Experiment 4: Hyperuricemia was induced in the same manner as in experiment 
3. Six-week-old male Wistar rats (mean body weight of 172.1 g) were divided into four 
groups (n= 6 for each group). The rats were administered 0 (vehicle), 30, 100, or 300 
mg/kg body weight of the peptide fraction; i.e., the ethanol-soluble fraction was 
suspended in distilled water at a concentration of 0, 6, 20, or 60 mg/ml (w/v) and 
administered orally at a constant volume of 5 ml/kg body weight via a stomach sonde. 
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One hour later, the rats were intraperitoneally injected with potassium oxonate solution 
(250 mg/2 ml of 3% gum arabic saline/kg body weight) in order to elevate their blood 
uric acid level. Whole blood samples were collected 1 h after the oxonate injection. To 
estimate the 50% inhibitory dose value (ID50), serum uric acid values were standardized 
against those of the normal and vehicle groups, which were taken as 0% and 100%, 
respectively. 
Experiment 5. Six-week-old male Wistar rats (mean body weight of 150.9 g) 
were divided into two groups (n=6 for each group). The rats were administered orally 0 
(vehicle) or 1 g/kg body weight of the ethanol-soluble fraction and intraperitoneally 
injected with potassium oxonate solution in the same manner in experiment 3. Whole 
blood samples were collected 1 h after the oxonate injection. The blood samples were 
stood for 0.5–1 h at room temperature to clot. The serum was then collected by 
centrifugation and stored at -30 °C until use. 
 
Xanthine oxidase inhibitory activity assay 
The xanthine oxidase assay was performed according to the method of Osada et 
al. (1993) with slight modifications. Xanthine was dissolved in 50 mM Tris–HCl buffer, 
pH 7.4, to give 15 mM. Xanthine oxidase was resolved in the same buffer to give 0.1 
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mU/l. The ethanol-soluble fraction was dissolved in the same buffer to give a suitable 
concentration. The substrate (40 l), enzyme (10 l), and sample solution (1950 l) were 
mixed and incubated for 10 min at 37ºC. The reaction was terminated by addition of 
50l of 3.2% (v/v) perchloric acid dis-solved in the same buffer. Absorbance at 292 nm 
was measured. Allopurinole and the buffer were used as positive and negative controls, 
respectively. Inhibitory activity is expressed as remaining activity against the negative 
control (%). For the evaluation of effect of ingestion of the ethanol-soluble fraction on the 
serum xanthine oxidase inhibitory activity, 200  l of serum from the rats in experiment 5 
were mixed with 3 vol. (v/v) of ethanol. The precipitate was removed by centrifugation at 
16,300g for 3 min. The supernatant was dried under vacuum and dissolved in the same 
buffer (1950  l) and used as sample. 
 
Other analytical procedures 
 The protein, mucopolysaccharide (glycosaminoglycan), lipid, moisture, and ash 
contents in the crude extract and ethanol-soluble fraction were determined according to 
the method of the Association of Official Analytical Chemists (1990). Amino acid 
analysis was performed according to the method of Bidlingmeyer et al. (1984) with a 
slight modification (Sato et al.; 1992). The determination of chondroitin sulfate was 
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performed according to the method of Bowness (1957).  Serum uric acid was measured 
using a Wako Uric Acid Test Kit (Wako Pure Chemical, Osaka, Japan) or the HPLC-UV 
method of the Committee on Biochemical Constituents and their Analytical Reagents 
(1993). The viscosity of a 20% sample water solution was measured using an RC-500 
(Toki Sangyo, Tokyo, Japan) at 100 rpm and 25 °C. To estimate water solubility, the 
quantity of water required to completely dissolve 1 g sample at 25 °C was determined. 
The molecular weights of the peptides were estimated by gel filtration chromatography 
using a TSKgel G3000PW l column (7.8300 mm; Tosoh, Tokyo, Japan) equilibrated 
with 45% acetonitrile containing 0.1% trifluoroacetic acid (TFA) and equipped with a 
Waters alliance 2965 HPLC system (Waters, Milford, MA, USA). The column was 
calibrated with glutathione (0.3 kDa), bradykinin (1.1 kDa),a-melanocyte stimulating 
hormone (MSH, 1.7 kDa), insulin chain B oxidized (3.5 kDa), aprotinin (6.5 kDa), 
cytochrome C (12.4 kDa), carbonic anhydrase (29.0 kDa), albumin (66.0 kDa), and 
alcohol dehydrogenase (150.0 kDa) as molecular weight markers, and a plot of log 
molecular weight versus Ve/Vt was used to estimate molecular weight, where Ve is the 
elution volume of each protein, and Vt is the retention volume of the total permeation 
peak. 
 
50 
 
Statistical analyses 
 Data are presented as the mean ± standard deviation. Differences between means 
were evaluated using the Student’s t-test or an analysis of variance followed by Dunnett’s 
test or the Bonferroni/Dunn method (p<0.05). Statistical analyses were performed with 
StatView Version 5.0 (Abacus Concept, Berkeley, CA, USA). 
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RESULTS 
Characterization of the ethanol-soluble fraction 
The 75% ethanol-soluble fraction had a yellow-white powdery appearance. The 
crude digest and ethanol-soluble fraction had their compositions and physical properties 
characterized as shown in Table 2. Acidic polysaccharides containing uronic acid, namely 
glycosaminoglycans, accounted for nearly half of the crude digest. On the other hand, 
most of the glycosaminoglycans had been removed from the ethanol-soluble fraction. 
Protein accounted for 99% of the ethanol-soluble fraction. Removing the 
glycosaminoglycans decreased the viscosity of the fraction to 1/27th of that of the crude 
digest and improved its solubility in water at 25°C by 3-fold compared to that of the 
crude digest. As shown in Table 3, the ethanol-soluble fraction had an amino acid 
composition similar to type II collagen. In shark type II collagen, hydroxyproline 
accounts for approximately 8% (mol/mol) of all amino acids. On the basis of its 
hydroxyproline content, approximately 75% of the peptides in the ethanol-soluble 
fraction were derived from type II collagen. As shown in Fig. 1, approximately 90% of 
the peptides in this fraction were distributed in the 0.3–7 kDa molecular mass range, and 
their mean molecular mass was estimated to be 1.5 kDa. 
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Animal experiments 
 Experiment 1: When the vehicle was administered, the serum uric acid levels of 
the rats that consumed the HU diet for 28 days were increased compared with those of the 
rats that ate the normal diet. The administration of the ethanol-soluble fraction (1 g/kg 
body weight) suppressed the development of hyperuricemia (Fig. 2A). There was no 
difference in body weight gain among any of the groups (data not shown). 
Experiment 2: In the normal rats, there was no significant difference in the 
serum uric acid level between the rats received the ethanol-soluble fraction (1 g/kg body 
weight) and vehicle for 28 days (Fig. 2B). There was no difference in body weight gain 
among any of the groups (data not shown). 
Experiment 3: In this experiment, hyperuricemia was induced in rats via a 
single intraperitoneal injection of oxonate. One hour before the oxonate injection, the test 
samples were administered orally. As shown in Fig. 3, a single dose of allopurinol 
decreased the serum uric acid level of the rats to below the normal level. A single 
administration of the ethanol-soluble fraction (1 g/kg body weight) also significantly 
decreased the serum uric acid level of the hyperuricemic rats in comparison to the 
administration of the vehicle and same dose of the crude digest. 
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Experiment 4: As shown in Fig. 4, a single administration of the ethanol-soluble 
fraction moderated hyperuricemia in a dose-dependent manner. A significant decrease in 
the serum uric acid level was observed at a dosage of 300 mg/kg. The 50% inhibitory 
dose value (ID50) of the ethanol-soluble fraction was estimated to be 262 mg/kg. 
 
Xanthine oxidase inhibitory activity 
As shown in Fig. 5A, the ethanol-soluble fraction did not show significant in 
vitro xanthine oxidase inhibitory activity even at relatively high dose. However, 
ingestion of the ethanol-soluble fraction significantly increases xanthine oxidase 
inhibitory activity in 75% ethanol-soluble fraction of the serum of rat (Fig. 5B). 
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DISCUSSION 
In the present study, a peptide fraction of nearly 99% purity was prepared from 
the shark cartilage microbial protease digest using simple selective 75% 
ethanol-extraction method. This fraction shows anti-hyperuricemic activity in two animal 
models by using different strains of rat. The efficacy at 1 g/kg body weight was 
significantly higher than the crude digest. On the other hand, purified chondroitin sulfate, 
one of the major glycosaminoglycans present in the crude shark cartilage digest, had no 
anti-hyperuricemic effect (chapter 2.). Taking these findings together, it can be concluded 
that the peptides in the digest are responsible for its anti-hyperuricemic activity in this rat 
model. In addition to increase of anti-hyperuricemic activity, the present ethanol-soluble 
fraction shows significantly lower viscosity and higher solubility than the crude digest by 
removal of glycosaminoglycans. Then, human subject can easily take it without difficulty 
in comparison to the crude digest. Low viscosity and high solubility in water are also 
advantageous with respect to manufacturing efficiency, which makes easy in filtration, 
etc. This ethanol soluble-fraction equivalent to the present peptide fraction can be also 
produced as a byproduct in the process of medical grade chondroitin sulfate. 
The present ethanol-soluble fraction predominantly consisted of peptides with 
molecular weights of less than 7 kDa and displayed a similar amino acid composition to 
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collagen. However, on the basis of their hydroxyproline content, approximately 25% of 
the peptides in the present fraction are derived from non-collagenous extracellular matrix 
proteins. To the best of our knowledge, there have been no reports about peptides with 
anti-hyperuricemic activity, except for imidazole dipeptides. They mildly moderate 
fatigue and consequently fatigue induced hyperuricemia in humans (Nishitani et al.; 2009, 
Quinlan et al.; 1997). However, only negligible amounts of -alanine, a constituent of 
imidazole dipeptides, were detected in the HCl hydrolysate of the present ethanol-soluble 
fraction. Therefore, non-imidazole peptides are responsible for the anti-hyperuricemic 
activity of the present ethanol-soluble fraction. Xanthine oxidase is a key enzyme for uric 
acid synthesis. Therefore, food components that are able to inhibit xanthine oxidase have 
been tested (Yoshizumi et al.; 2005). However, few peer-reviewed papers have 
demonstrated that ingestion of food components display anti-hyperuricemic activity 
based on xanthine oxidase inhibition. The present study in this chapter clearly indicates 
that inhibition of xanthine oxidase is involved in the anti-hyperuricemic activity by 
ingestion of the ethanol-soluble fraction (Fig. 5B). However, the ethanol-soluble fraction 
had no significant in vitro xanthine oxidase inhibitory activity (Fig. 5A). Then, 
conventional in vitro activity-guided fractionation based on xanthine oxidase inhibition 
assay cannot be used for identification of the active peptide in the ethanol-soluble fraction. 
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The apparent inconsistency between in vitro and in vivo results could be explained as 
follow. After ingestion of the ethanol-soluble fraction, smaller peptides or their 
metabolites with xanthine oxidase inhibitory activity might be produced from parent 
peptides in the ethanol-soluble fraction during digestion, absorption, metabolism 
processes. A further study based on in vivo activity-guided fractionation for identification 
of the anti-hyperuricemic peptides in the digest is described in chapter 4. 
Peptides in a shark cartilage microbial protease digest are responsible for the 
anti-hyperuricemic activity by oral administration. The peptide fraction of the shark 
cartilage digest with higher anti-hyperuricemic activity and lower viscosity than crude 
digest can be prepared using by simple 75% ethanol extraction, which can be used for the 
preparation of food ingredients. Therefore, this preparation has potential as a functional 
food ingredient with anti-hyperuricemic activity and consumer-friendly textural 
properties. Inhibition of uric acid synthesis is demonstrated to be involved in the 
anti-hyperuricemic activity of the present preparation. 
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TABLES AND GRAPHS 
Table 1. Compositions of normal and oxonate diets used in experiment 1. 
   (%) 
 Normal diet Hyperuricemic (HU) diet 
Corn starch 38.0 38.0 
Casein 25.0 25.0 
α-corn starch 10.0 10.0 
Cellulose 8.0 8.0 
Soybean oil 6.0 6.0 
Mineral mix (Oriental) 6.0 6.0 
Vitamin mix (Oriental) 2.0 2.0 
Sucrose 5.0 2.5 
Potassium oxonate - 2.5 
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Table 2  Approximate composition and physical properties of a shark cartilage 
digest and its ethanol-soluble fraction. 
Component Crude shark cartilage digest Peptide fraction 
Protein 53% 99% 
Mucopolysaccharides 43% 0.6% 
Lipids < 0.1% 0.1% 
   
Apparent viscosity of 20% solution at 25 °C 35.1 mPa·s 1.3 mPa·s 
Water solubility (1g) 6.0 ml 2.0 ml 
Data are shown as the mean values of duplicate determinations. 
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Table 3.  Amino acid (g/100 g of protein) profile of the ethanol-soluble fraction. 
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His 1.2 0.9 
Arg 6.1 5.9 
 
 
 
Figure 1 Elution profile of the ethanol-soluble fraction on gel filtration 
chromatography and a profile of standard proteins .  
The column was calibrated with A: glutathione (0.3 kDa), B: bradykinin (1.1 kDa), C: 
alpha-MSH (1.7 kDa), D: insulin chain B oxidized (3.5 kDa), E: aprotinin (6.5 kDa), F: 
cytochrome C (12.4 kDa), G: carbonic anhydrase (29.0 kDa), H: albumin (66.0 kDa), and 
I: alcohol dehydrogenase (150.0 kDa) as molecular weight markers, and a plot of log 
molecular weight versus (Ve/V0) was used to estimate molecular weight (lower graph). 
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Figure 2. Effect of the orally administered ethanol-soluble fraction on the serum 
uric acid level of rat models. 
Graphs are presented for the serum uric acid level of a rat model. A: Rats were fed the 
HU diet containing 2.5% oxonate or the normal diet and then received vehicle (normal 
and HU) or the ethanol-soluble fraction for 28 days (experiment 1). * Indicates a 
significant difference to the HU group (p < 0.05; Dunnett). B: Rats were fed the normal 
diet and then received vehicle or the ethanol-soluble fraction for 28 days (experiment 2). 
Hyperuricemic rat; 
Normal rat; 
*
*
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Figure 3.  The serum uric acid lowering effects by single administration of the 
ethanol-soluble fraction, crude digest, and allopurinol. 
Graph is presented for the serum uric acid level of a rat model (experiment 3) 
administered orally the ethanol-soluble fraction, crude digest, or allopurinol followed by 
oxonate treatment. Normal; rat without oxonate treatment. Different letters indicate a 
significant difference within groups (p < 0.05; Bonferroni/Dunn). ++ Indicates a 
significant difference between the vehicle group and the normal or crude digest group (p 
< 0.01; Student’s t-test). 
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Figure 4. Dose-dependent serum uric acid lowering effect of the ethanol-soluble 
fraction.  
Graph is presented for the serum uric acid level of a rat model administered the 
ethanol-soluble fraction orally in the dose-finding study (experiment 4). To estimate ID50, 
serum uric acid values were standardized against those of the normal and vehicle groups, 
which were taken as 0% and 100%, respectively. * indicates a significant difference 
between the vehicle group (p < 0.05; Dunnett). 
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Figure 5. In vitro and in vivo xanthine oxidase inhibition by the ethanol-soluble 
fraction of shark cartilage digest.  
A:Remaining xanthine oxidase activity after addition of the ethanol-soluble fraction. 
Allopurinol was used as positive control.  
B: Remaining xanthine oxidase activity after addition of the ethanol-soluble fraction of 
the serum of Wister strain rat after ingestion of vehicle and ethanol-soluble fraction 
(experiment 5). The remaining activity was standardized against that of the vehicle 
groups, which were taken as 100%. 
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Chapter 4. 
Identification of anti-hyperuricemic peptides in the proteolytic digest of 
shark cartilage water extract by using in vivo activity-guided 
fractionation 
 
ABSTRACT 
A peptide that exerts anti-hyperuricemic activity after oral administration was 
identified from a microbial protease (alcalase) digest of the water extract of shark 
cartilage by in vivo activity-guided fractionation, using oxonate-induced hyperuricemic 
rats. Water extract of shark cartilage was first fractionated by preparative ampholine-free 
isoelectric focusing and followed by preparative reversed-phase liquid chromatography. 
The anti-hyperuricemic activity of the alcalse digests of the obtained fractions was 
evaluated using an animal model. Alcalase digests of the basic and hydrophobic fractions 
exerted anti-hyperuricemic activity. Eighteen peptides were identified in the alcalase 
digest of the final active fraction. These peptides were chemically synthesized and 
evaluated for anti-hyperuricemic activity. Tyr-Leu-Asp-Asn-Tyr and 
Ser-Pro-Pro-Tyr-Trp-Pro-Tyr lowered serum uric acid level via intravenous injection at 5 
mg/kg body weight. Furthermore, orally administered Tyr-Leu-Asp-Asn-Tyr showed 
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anti-hyperuricemic activity. Therefore, these peptides are at least partially responsible for 
the anti-hyperuricemic activity of the alcalase digest of shark cartilage.  
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INTRODUCTION 
As mentioned in chapter 2. and 3., it is demonstrated that oral administration of a 
crude proteolytic digest of shark cartilage lowers serum uric acid levels in the potassium 
oxonate-induced hyperuricemic rat (Murota et al.; 2010). The crude digest contained a 
mixture of chondroitin sulfate and peptides. The previous study as described in chapter 2. 
demonstrated that chondroitin sulfate has no significant anti-hyperuricemic activity. 
These results imply that peptides may be responsible for the anti-hyperuricemic activity 
(Murota et al.; 2012). However, the anti-hyperuricemic peptide in the digest has not yet 
been identified. 
  Administration of the ethanol-soluble fraction of the digest (1 g/kg body 
weight/day) significantly increased serum inhibitory activity against xanthine oxidase, 
whereas the ethanol-soluble fraction had no in vitro xanthine oxidase inhibitory activity. 
These facts suggest that peptides in the ethanol-soluble fraction might be converted into 
smaller peptides with xanthine oxidase inhibitory activity during digestion and absorption 
process. 
       The objective of the present study in this chapter is to identify the active peptide, 
which shows anti-hyperuricemic activity by oral ingestion in the animal model. 
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MATERIALS AND METHODS 
Regents.  Synthetic peptides were purchased from ILS (Ibaraki, Japan). These peptides 
were synthesized using the 9-fluorenylmethyloxycarbonyl (Fmoc) strategy. The purity of 
the peptides was checked by electron spray ionization mass spectrometer using a LCQ 
Advantage (Thermo Fisher Scientific, Waltham, MA). The Uric Acid Test Wako Kit, 
trifluoroacetic acid (TFA), acetonitrile (HPLC grade) were purchased from Wako Pure 
Chemical (Osaka, Japan). Potassium oxonate was purchased from Across Organics (Geel, 
Belgium). Shark cartilage chondroitin sulfate C was purchased from Sigma (St. Louise, 
MO). Alcalase (5U/g) was obtained from Novozymes (Bagsvaerd, Denmark). Other 
reagents were of analytical grade or better. 
 
Preparation of Shark Cartilage Water Extract.  The water extract of cartilage from 
blue shark (Prionace glauca) fin was prepared using the previously reported method 
(Kitahashi et al; 2012). Blue sharks were caught by longline fishing and was stored at 
Kesen-Numa Port in Miyagi Prefecture, Japan. The fin was collected and solar-dried. The 
dried fin was rehydrated in 50-60C water for approximately 30 min. The fin was skinned 
and collagenous transparent fibers, which are used in gourmet Chinese cuisine, were 
removed. The remaining cartilage was solar-dried. The dried fin cartilage was crushed 
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with liquid nitrogen in a Lindex mill (Hosokawa Micron, Osaka, Japan). Three hundred 
grams of the fine powder (60 m in average diameter) was mixed with 1.5 L of cold 
water. The suspension was allowed to stand for 30 min. with occasional stirring. The 
supernatant was harvested by centrifugation at 1000  g using a No. 9 rotor (Tomy Seiko, 
Tokyo, Japan). The pellet was further extracted with 500 mL of cold water. The 
supernatants were combined and used for the following experiments 
 
Fractionation of water-soluble components for animal experiment.  Compounds in 
the water-extract were fractionated by ampholyte-free preparative isoelectric focusing, 
which is referred to as autofocusing, using the method described by Hashimoto et al. 
(2005) using an autofocusing apparatus with 10 sample compartments (75 mm in length  
80 mm in width  85 mm in height for each compartment). The water-extract was placed 
in sample compartments No. 5 and 6. The other compartments were filled with deionized 
water. Autofocusing was carried out at 500 V for 18 h. The autofocusing fractions were 
freeze-dried.  
       The autofocusing fraction that exerted anti-hyperuricemic activity after alcalase 
digestion was subjected to preparative reversed-phase liquid chromatography. YFLC gel 
C18 (particle size 40 m in diameter; Yamazen, Osaka, Japan) was packed into a column 
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(250 mm  15 mm i.d.) and equilibrated with 10% (v/v) acetonitrile in the presence of 
0.1% TFA. Two grams of the dried active autofocusing fraction without alcalase digestion 
was dissolved into 100 mL of the equilibrium solvent and loaded into the column using 
an MPLC system (Yamazen) at 10 mL/min. After loading of the sample, the column was 
washed with 100 mL of the equilibrium solvent. After elution of the non-absorbed 
components, the absorbed components were eluted with a linear gradient of acetonitrile 
from 10 to 80% in the presence of 0.1% TFA over 20 min. Fractions were collected every 
1 min.  Elution was monitored by absorbance at 280 nm. 
 
Alcalase Digestion.  Prior to conducting the animal experiment, an aliquot of each 
fraction was digested with alcalase. The sample was dissolved in water to yield 8% (w/v) 
and adjusted to pH 8.0 by addition of NaOH or HCl. Alcalase (liquid form) was added at 
a ratio of 0.04% (v/v) to the reaction mixture and reacted at 60C for 4 h. The reaction 
was terminated by heating to 85C for 10 min. The reaction product was freeze-dried and 
stored at 20C until use. 
 
Animal Experiment.  Male Wistar rats were purchased from Charles River 
Laboratories Japan (Yokohama, Japan).  All diet pellets were purchased from Oriental 
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Yeast (Tokyo, Japan). All animals were housed (temperature: 22-24°C, humidity: 
40-60%) in the same building under a 12-hours light-dark cycle and given free access to 
diet pellets and filtered water. The rats were allowed to adapt to the environment for a 
week before the start of the experiment. This study was conducted in accordance with the 
standards established by the Guide for the Care and Use of Laboratory Animals of 
Maruha Nichiro Holdings Central Research Institute (Tsukuba-City, Japan).  
       The test components were suspended in distilled water at an appropriate 
concentration and administered at a constant volume of 5 mL/kg body weight to the rats 
via a stomach sonde. The doses of fractions (mg/kg body weight) are shown in Figures. 
The rats in the control group were administered the same volume of distilled water 
(vehicle). In some cases, test components were dissolved in saline and injected into the 
tail vein. Before the injection, the sample was sterilized by passing through a filter (0.45 
m pore size, GL Sciences, Tokyo, Japan). One hour after the administration of test 
components, rats received a potassium oxonate solution (250 mg/2 mL of 3% gum arabic 
saline/kg body weight) by intraperitoneal injection to elevate their blood uric acid level 
(Murota et al.; 2010, Murota et al.; 2012, Osada et al.; 1993). One hour after the oxonate 
injection, blood samples were collected from the caudal artery under pentobarbital 
anesthesia. Rats were starved for more than 12 hours before their blood was drawn. 
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Isolation of peptides in the alcalase digest of active fraction.  Peptides were obtained 
from the alcalase digest of the active fraction by preparative reversed-phase liquid 
chromatography, and were resolved by a size-exclusion chromatography (SEC) and 
reversed-phase high performance liquid chromatography (RP-HPLC). One milligram of 
the alcalase digest of the active fraction was dissolved in 200L of 30% acetonitrile in 
the presence of 0.1% TFA and loaded into a Superdex peptide 10/30 HR (GE Healthcare, 
Buckinghamshire, UK), which had been equilibrated with 30% acetonitrile in the 
presence of 0.1% TFA at a flow rate 0.5 mL/min. Fractions were collected every 1 min. 
The SEC fractions were dried under vacuum and dissolved in 200 L of 10% acetonitrile 
in the presence of 0.1% TFA and further fractionated using a Cosmosil 5C18-MS-II (250 
 4.6 mm i.d., Nacalai Tesque, Kyoto, Japan). Elution was performed using a linear 
gradient of acetonitrile from 10 to 80% in the presence of 0.1% TFA for 30 min at a flow 
rate of 1 mL/min. Absorbance at 214 nm was monitored. The column was maintained at 
40C. 
Other Analytical Methods.  Protein content was evaluated by amino acid analysis after 
HCl hydrolysis. Amino acid analysis was performed according to the method described 
by Bidlingmeyer et al. (1984) with slight modifications (Higaki et al.; 2003). The peptide 
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sequence was analyzed using the Edman degradation procedure using a PPSQ-21 
(Shimadzu, Kyoto, Japan). Chondroitin sulfate was determined by the carbazole sulfate 
method using shark cartilage chondroitin sulfate C as a standard (Bowness; 1957). 
       The xanthine oxidase assay was performed according to the method of Osada et 
al. (1993) with slight modifications (Murota et al.; 2012)  Xanthine was dissolved in 50 
mM Tris–HCl buffer, pH 7.4, to give 15 mM. Xanthine oxidase was resolved in the same 
buffer to give 0.1 mU/mL. Sample was dissolved in the same buffer to give a suitable 
concentration. The substrate (40 L), enzyme (10 L), and sample solution (1950 L) 
were mixed and incubated for 10 min at 37ºC. The reaction was terminated by addition of 
50 L of 3.2% (v/v) perchloric acid. Absorbance at 292 nm was measured. Allopurinole 
and the buffer were used as positive and negative controls, respectively. Inhibitory 
activity is expressed as remaining activity against the negative control (%). For the 
evaluation of effect of ingestion of Tyr-Leu-Asp-Asn-Tyr on the serum xanthine oxidase 
inhibitory activity, 100 L of serum from the rats received the peptide, vehicle, and 
allopurinol were mixed with the buffer (1850 L) and used as sample solution. Doses of 
peptide are shown in Figure legend. 
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Statistical Analysis.  Data are presented as the mean ± standard deviation. Differences 
in serum uric acid levels were analyzed by one-way analysis of variance and Scheffe’s 
post hoc test using StatView 4.11 (Abacus Concepts Inc., Berkeley, CA, USA). 
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RESULTS 
       As shown in Figure 1, the intact water-extract did not show significant 
anti-hyperuricemic activity. However, the alcalase digest showed significant uric-acid 
lowering activity to the oxonate-induced hyperuricemic rat by oral administration at 1 
g/kg of body weight, indicating that peptides produced from the parent proteins in the 
water extract by alcalase digestion are responsible for the anti-hyperuricemic activity. The 
intact water-soluble components of the shark cartilage were fractionated on the basis of 
their isoelectric points by autofocusing. As shown in Figure 2, acidic (fraction number 
1–5), weakly acidic (6–7), and basic fractions (8–10) were collected. Solid components 
were recovered from the acidic, weakly acidic, and basic fractions at 66, 24, and 10%, 
respectively. The acidic and weakly acidic fractions consisted of protein and chondroitin 
sulfate. In contrast, the basic fraction predominantly consisted of protein. The three 
fractions were digested with alcalase and the digests were orally administered to the 
oxonate-induced hyperuricemic rats. The dose of each fraction was determined on the 
basis of the recovery percentage. Only the alcalase digest of the basic fraction 
significantly reduced serum uric acid level at 0.1 g/kg of body weight, which is less than 
that of the water-extract (1 g/kg) or the other fractions.  
       The proteins in the basic fraction were further fractionated by preparative 
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reversed-phase liquid chromatography without alcalase digestion. As shown in Figure 3, 
three peaks (Fractions 2-4) were eluted by gradient elution after elution of the unabsorbed 
components (Fraction 1). These fractions were also digested with alcalase and evaluated 
for their anti-hyperuricemic activity. The dose of each fraction was determined on the 
basis of recovery percentage. Only the alcalase digest of Fraction 4 showed significant 
anti-hyperuricemic activity by oral administration at 50 mg/kg body weight. 
       The peptides in the alcalase digest of the Fraction 4 were first resolved by SEC. 
Fractions were collected every 1 min. The SEC fractions eluted between 29 and 35 min 
were subjected to analytical RP-HPLC. As shown in Figure 4, the two-dimensional 
HPLC provided excellent resolution of the constituent peptides. The peptides marked 
with large characters were collected and subjected to sequence analysis. The obtained 
sequences are summarized in Table 1. All peptides contained aromatic amino acids: 
tyrosine, phenylalanine, and tryptophan. On the basis of the sequence data, all peptides 
were chemically synthesized and evaluated for anti-hyperuricemic activity. As shown in 
Figure 5, Tyr-Leu-Asp-Asn-Tyr and Ser-Pro-Pro-Tyr-Trp-Pro-Tyr showed significant 
anti-hyperuricemic activity by intravenous injection at 5 mg/kg (P<0.01 and <0.05, 
respectively). However, Asp-Phe-Trp-Arg-Tyr (DFWRY) and other peptides did not show 
significant anti-hyperuricemic activity (data not shown).  Oral administration of the 
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Tyr-Leu-Asp-Asn-Tyr also significantly reduced serum uric acid at 50 mg/kg body weight 
(Figure 5), while Ser-Pro-Pro-Tyr-Trp-Pro-Tyr did not show significant activity by oral 
ingestion. Oral administration of Tyr-Leu-Asp-Asn-Tyr also significantly increased serum 
inhibitory activity against xanthine oxidase at same dose (Figure 6). The xanthine oxidase 
inhibitory activity of Tyr-Leu-Asp-Asn-Tyr and possible fragment peptides is shown in 
Table 2.  Asp-Asn, Leu-Asp-Asn, Asp-Asn-Tyr, and Leu-Asp-Asn-Tyr showed 
inhibitory activity, while Tyr-Leu-Asp-Asn-Tyr and constituting amino acids did not 
show the inhibitory activity. The IC50 of these fragment peptides were 13-23 times higher 
than that of allopurinol. 
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DISCUSSION 
Over the last few decades, numerous studies have demonstrated that ingestion of food 
protein hydrolysates has significant biological effects, such as moderation of 
hypertension, hypertriglyceridemia, hypercholesteremia, etc. The active peptides have 
been identified using activity-guided fractionation based on in vitro assay systems using 
enzyme reactions and cell culture systems. Using this approach, many peptides have been 
apparently identified as active compounds. However, unlike other functional ingredients, 
proteins and peptides are further degraded into smaller peptides and constituent amino 
acids during digestion and absorption. As a result, the peptides in food may lose the 
potential biological activity detected by in vitro assays. Therefore, the in vitro activity of 
the peptides in the food cannot be directly linked to their biological activity after 
ingestion. To resolve these questions, the biological activity of potentially active peptides 
should be evaluated by feeding experiments using animal models. However, this 
approach requires relatively large amounts of peptide in comparison to the in vitro assays.  
For this approach, we have developed large-scale ampholyte-free preparative isoelectric 
focusing, referred to as autofocusing, which can process peptide samples up to 50-500 g 
(Murota et al.; 2012). Coupled with preparative reversed-phase chromatography, the 
parent protein, which produced anti-hyperuricemic peptides after alcalase digestion, was 
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recovered from the basic and hydrophobic fractions (Figures 3 and 4). The alcalase digest 
of the final fraction exerted significant uric acid-lowering activity at a 1/20 dose in 
comparison to the crude digest. All peptides identified in the digest consisted of aromatic 
amino acids. Similarity research analyses using FAST and BLAST protocols revealed that 
these peptide sequences are similar to mammalian hypothetical proteins, of which the 
function is unknown. Using peptides synthesized on the basis of the sequence data, two 
peptides were identified, which exerted anti-hyperuricemic activity by intravenous 
injection at 5 mg/kg of body weight. Among these peptides, oral administration of 
Tyr-Leu-Asp-Asn-Tyr at 50 mg/kg of body weight exerted anti-hyperuricemic activity, 
which indicates that this peptide plays a significant role in the anti-hyperuricemic activity 
of shark cartilage extract. However, the dose of Tyr-Leu-Asp-Asn-Tyr necessary for the 
significant anti-hyperuricemic activity by oral ingestion was comparable to the required 
dose of the alcalase digest of the final fraction (Fraction 4 in Figure 3). The presence of 
other peptides in the digest may enhance the anti-hyperuricemic activity of 
Tyr-Leu-Asp-Asn-Tyr by oral ingestion.  
   Our previous study demonstrated that ingestion of a protease digest of shark cartilage 
increases serum inhibitory activity against xanthine oxidase, a key enzyme for uric acid 
synthesis, whereas the digest has no in vitro xanthine oxidase inhibitory activity. 
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Tyr-Leu-Asp-Asn-Tyr also had no in vitro xanthine oxidase inhibitory activity (Table 2), 
whereas it increased serum xanthine oxidase inhibitory activity by ingestion (Figure 6). It 
has been demonstrated that most of the food-derived peptides in blood are tri- and 
di-peptides even after ingestion of larger peptides.17-19 Then Tyr-Leu-Asp-Asn-Tyr may 
be further degraded into smaller peptides with xanthine oxidase inhibitory activity and 
absorbed into the blood system. Indeed, some di-, tri-, and tetra-peptides, which could be 
potentially derived from Tyr-Leu-Asp-Asn-Tyr, show xanthine oxidase inhibitory activity. 
Asp-Asn motif is contained in all xanthine oxidase inhibitory peptides. These facts 
suggest that these fragment peptides might be absorbed into blood and exert 
anti-hyperuricemic activity by inhibition of xanthine oxidase. Alternatively, the 
degradation peptides may induce endogenous xanthine oxidase inhibitors. Further studies 
on the metabolic fate of Tyr-Leu-Asp-Asn-Tyr and other peptides in the active fraction 
and on the identification of increased endogenous or food-derived xanthine oxidase 
inhibitors in serum after ingestion of these peptides are currently in progress to elucidate 
the mechanism of the anti-hyperuricemic activity. 
       The active peptide Tyr-Leu-Asp-Asn-Tyr in the alcalase digest of crude shark 
cartilage can be separated from chondroitin sulfate and other high molecular weight 
components by simple selective precipitation technique using 75% ethanol, which can 
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decrease dose to exert anti-hyperurecemic activity by ingestion (Iawi et al.;2005).  
Therefore, the peptide concentrate has potential as a functional food ingredient with 
anti-hyperuricemic activity. 
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TABLES AND GRAPHS 
Table 1. Summary of sequences of peptides from the alcalase digest of the Fraction 4 
Peak Sequence 
A Leu-Pro-Tyr O Tyr-Phe 
B Tyr-Leu-Asp-Asn-Tyr P Tyr-Tyr 
C Asp-Phe-Trp-Arg-Tyr Q Ser-Asn-Trp-Gln 
D Ser-Pro-Pro-Tyr-Trp-Pro-Tyr R Phe-Tyr 
E Ser-Leu-Pro-Tyr-Trp-Pro-Tyr 
F Ile-Asn-Tyr 
G Val-Tyr-Gln 
H Tyr-Asn-Leu 
I Leu-Tyr 
J Ser-Ile-Tyr-Asp 
K Phe-Tyr 
L Tyr-Leu 
M Arg-Tyr-Leu 
N Gly-Tyr-Leu 
Refer to Figure 4 for peak names. 
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Table 2. Xanthine oxidase Inhibitory activity of possible fragment peptides from 
Tyr-Leu-Asp-Asn-Tyr  
Sample 
Remaining activity (%) 
Dose (M) 
110-5      110-4       310-4         110-3 
IC50 (M) 
Allopurinol 73.129.5 25.87.2* 11.510.6* 12.36.7* 3.810-5 
Tyr-Leu 102.2 2.1 106.43.1 98.710.2 106.92.7 - 
Leu-Asp 104.71.0 107.75.9 88.932.8 59.719.7 - 
Asp-Asn 103.52.0 107.87.1 83.217.9 16.211.1* 5.010-4 
Asn-Tyr 105.24.1 108.36.0 101.89.1 86.013.1 - 
Try-Leu-Asp 103.52.0 108.65.5 103.19.9 79.624.1 - 
Leu-Asp-Asn 95.016.9 84.416.7 98.612.1 35.811.5* 7.610-4 
Asp-Asn-Tyr 106.67.4 87.728.5 86.618.2 45.712.7* 8.810-4 
Tyr-Leu-Asp-Asn 109.010.7 108.16.9 102.310.9 57.125.2* - 
Leu-Asp-Asn-Tyr 104.22.7 108.46.3 99.66.1 34.418.9* 7.510-4 
Try-Leu-Asp-Asn-Tyr 100.27.7 101.51.3 - 101.70.2 - 
Allopurino and distilled water were used as positive and negative controls, respectively. Remaining 
activity of xanthine oxidase is expressed as percent of the negative control (mean  standard 
deviation, n=3).  *indicates a significant difference vs the negative control P< 0.05. 
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Figure 1. Effect of supplementation of the water extract of shark cartilage (undigest) 
and its alcalase digest (digest) on serum uric acid levels of rats treated with 
potassium oxonate.  
Data present the mean ± standard deviation (n=6).  Data points marked with different 
letters indicate significant differences (P<0.01). 
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Figure 2. First purification of the protein that produces peptides with 
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anti-hyperuricemic activity after alcalase digestion using ampholyte-free 
preparative isoelectric focusing (autofocusing).  
The water extract of shark cartilage without alcalase digestion was fractionated by 
autofocusing (lower). Acidic, weakly acidic, and basic fractions were collected as 
indicated by bars. *Protein content is expressed as the sum of the constituting amino 
acids in the HCl hydrolysate. An aliquot of each fraction was evaluated for 
anti-hyperuricemic activity after alcalase digestion (upper). Dosages were determined  
by the following equation: (ratio of each fraction to start material)  1g/kg body weight. 
Data present the mean ± standard deviation (n=6). Data marked with ** are significantly 
different from the cntrol group treated with potassium oxonate at P<0.01.
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Figure 3.  Second purification of the protein that produces peptides with 
anti-hyperuricemic activity after alcalase digestion by preparative reversed-phase 
chromatography. 
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The basic fraction shown in Figure 2, without alcalase digestion, was used (lower). The 
arrow represents the start of gradient elution. Effluents were collected every minute and 
gathered to Fraction (Fr.) 1-4, as shown. An aliquot of each fraction was evaluated for 
anti-hyperuricemic activity after alcalase digestion (upper). Dosages (mg/kg body 
weight) are presented in parentheses. Data present the mean ± standard deviation (n=6). * 
and ** indicate significant difference from the control group (Vehicle) treated with 
potassium oxonate at P<0.05 and 0.01, respectively 
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Figure 4. Isolation of peptides from the alcalase digest of the hydrophobic fraction 
(Fraction 4 in Figure 3).  
The alcalase digest was first subjected to size-exclusion chromatography (SEC). Fractions 
were collected every minute. SEC fractions (Fr. 31–35) were further fractionated by 
RP-HPLC. Peaks marked with large characters were collected and subjected to sequence 
analysis. Sequences of the identified peptides are summarized in Table 1.
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Figure 5. Anti-hyperuricemic activity of the synthetic peptides. 
Asp-Phe-Trp-Arg-Tyr (DFWRY), Tyr-Leu-Asp-Asn-Tyr (YLDNY), and 
Ser-Pro-Pro-Tyr-Trp-Pro-Tyr (SPPYWPY) were injected into the tail vein (5 mg/kg body 
weight) (upper).  YLDNY was also orally administered (lower).
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Figure 6.  Inhibitory activity against xanthine oxidase by serum from the rat that 
had ingested vehicle (V), allopurinol (AP), and Tyr-Leu-Asp-Asn-Tyr 2 h before 
collection of blood.  
Data presents the mean ± standard deviation (n=6). * indicates significant difference from 
the control group (V) at P<0.05.
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Chapter 5. General discussion and conclusion.  
Xanthine oxidase is a key enzyme for uric acid synthesis. Therefore, food 
components that are able to inhibit xanthine oxidase have been tested to obtain serum uric 
acid lowering food ingredient (Yoshizumi, et al.; 2005). However, few peer-reviewed 
papers have demonstrated that ingestion of food components display anti-hyperuricemic 
activity based on xanthine oxidase inhibition. For one reason, the components, which had 
been screened by in vitro inhibitory assay against xanthine oxidase, might be metabolized 
and lose the potential inhibitory activity during digestion and absorption process. To 
break this situation, uric acid lowering activity was evaluated by feeding experiment 
using oxonate-induced hyperuricemia rat model. After confirming the uric acid lowering 
activity of proteolytic digest of shark cartilage, in vivo activity-guided fractionation based 
on large-scale fractionation and animal experiment was used to identify the active 
peptide. 
Tyr-Leu-Asp-Asn-Tyr was successfully identified by this approach as serum uric acid 
lowering peptide by ingestion. Tyr-Leu-Asp-Asn-Tyr intact does not show xanthine 
oxidase-inhibiting activity, while ingestion of Tyr-Leu-Asp-Asn-Tyr decreased serum 
xanthine oxidase activity. Therefore, Tyr-Leu-Asp-Asn-Tyr cannot be identified by using 
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the conventional in vitro xanthine oxidase inhibitory assay, which indicates advantage of 
the present approach to the conventional one.  
Only Tyr-Leu-Asp-Asn-Tyr exerted serum uric acid lowering effect by oral 
administration in the active fraction that had been prepared by autofocusing and 
preparative reversed phase liquid chromatography. These facts indicate that 
Tyr-Leu-Asp-Asn-Tyr plays significant role in serum uric acid lowering effect in the 
proteolytic digest of shark cartilage. However, effective dose for serum uric acid lowering 
effect of Tyr-Leu-Asp-Asn-Tyr was comparable to the final active fraction, which 
indicates that other peptides in the active fraction might enhance the activity of 
Tyr-Leu-Asp-Asn-Tyr, while these peptides do not exert uric acid lowering activity alone. 
Effect of other peptides in the active fraction on uric acid lowering effect of 
Tyr-Leu-Asp-Asn-Tyr should be examined. Identification of Tyr-Leu-Asp-Asn-Tyr and 
other peptides in the active fraction enable examine it.  
    Mechanism for decrease of serum xanthine oxidase activity by ingestion of shark 
cartilage digest and Tyr-Leu-Asp-Asn-Tyr remains to be solved. As Tyr-Leu-Asp-Asn-Tyr 
has no inhibitory activity against xanthine oxidase, its fragment peptides might directly 
inhibit it. Alternatively, Tyr-Leu-Asp-Asn-Tyr or its fragment peptides might induce 
endogenous inhibitors. Further investigation is necessary to elucidate the mechanism for 
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the decrease in the serum uric acid level observed after the intake of crude shark cartilage 
extract and Tyr-Leu-Asp-Asn-Tyr.  
The serum uric acid lowering activity in the crude shark cartilage extract can be 
concentrated by removal of chondroitin sulfate by ethanol precipitation, which can be 
used for food manufacture. By this simple treatment, dose for serum uric acid lowering 
activity can be decreased, which would facilitate human trial. If serum uric acid lowering 
effect of the ethanol extract is confirmed by well-designed human trial, it would be used 
as functional ingredient to moderate hyperuricemia. 
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